Relative Benefit of Dual Versus Single Antiplatelet Therapy Among Patients With Atrial Fibrillation on Oral Anticoagulation According to Time After ACS and PCI: Insights From the AUGUSTUS Trial
Authors' conclusion
Among patients with atrial fibrillation with acute coronary syndrome or undergoing percutaneous coronary intervention, there was no difference in the relative benefit of apixaban versus vitamin K antagonist or aspirin versus placebo when patients were enrolled early versus later after their index event.
Study context
- Population
- Patients with AF and ACS or PCI on oral anticoagulationwith time-to-enrolment data
- Participants
- 4,605 patients
- Comparison
- Aspirin vs placebo and apixaban vs VKA, by time from index ACS/PCI to enrolment (<6 vs ≥6 days)
Methodological detailsopen-label, 2 x 2 factorial
- Open-label
- 2 x 2 factorial
Primary result
As reported in the abstract
Death or ischemic events, by time from index event (subgroup) · 30 days
Aspirin vs PlaceboHazard ratio (95% CI)
Time from index event <6 days
0.55(0.30–0.99)
Time from index event ≥6 days
0.88(0.54–1.43)
Further findings
- Median time from index event to enrolment (range 0-14) days
- 6
Original publication
Relative Benefit of Dual Versus Single Antiplatelet Therapy Among Patients With Atrial Fibrillation on Oral Anticoagulation According to Time After ACS and PCI: Insights From the AUGUSTUS Trial. Circ Cardiovasc Interv. Published 6 November 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →